# Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

> **NCT02611960** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 233 (actual)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02611960
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-18
- **Primary completion:** 2020-11-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611960, "Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02611960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*